Quick Answer
Neumora Therapeutics, Inc. reported R&D Expense of $176.06 million for fiscal year 2025.
Neumora Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $176.06M | -12.4% |
| 2024 | $200.93M | +40.8% |
| 2023 | $142.72M | +55.6% |
| 2022 | $91.75M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.52M | -33.2% | +4.6% |
| June 30, 2025 | $38.72M | -20.4% | -25.7% |
| March 31, 2025 | $52.15M | +14.0% | -14.0% |
| September 30, 2024 | $60.63M | +45.7% | +24.7% |
| June 30, 2024 | $48.63M | +48.4% | +6.3% |
| March 31, 2024 | $45.76M | +55.2% | +10.0% |
| September 30, 2023 | $41.60M | +84.5% | +27.0% |
| June 30, 2023 | $32.77M | — | +11.1% |
- Neumora Therapeutics, Inc. showed a decrease of -12.4% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s r&d expense has grown by 91.9% (from $91.75 million to $176.06 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: